ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
WALTHAM, Mass., Feb. 14, 2018 -- Radius Health, Inc. (Nasdaq:RDUS) announced today that it will release its fourth quarter and full year 2017 financial results on Thursday, March 1, 2018. The Company will host a conference call and live audio webcast at 4:30 p.m. ET that day to discuss the results and provide a company update.
Conference Call Information
Date: Thursday, March 1, 2018
Time: 4:30 p.m. ET
Domestic Dial-in Number: (866) 323-7965
International Dial-in Number: (346) 406-0961
Conference ID: 3484256
Live webcast: https://edge.media-server.com/m6/p/rw74zpqc
A replay of the conference call/webcast will be available from March 1, 2018 at 7:30 p.m. ET until March 8, 2018 at 7:30 p.m. ET. To access the replay, dial (855) 859-2056 for U.S. or (404) 537-3406 for International. The replay conference ID is 3484256.
The live audio webcast of the call can be accessed from the Investors section of the Company's website, www.radiuspharm.com, and a webcast replay will also be available for 14 days. The full text of the announcement and financial results will also be available on the Company's website.
About Radius Health
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com, and follow us on Twitter and LinkedIn.
Investor Relations Contact:
Elhan Webb, CFA
Email: [email protected]
Phone: 617-551-4011
